PREAMBLE
Medicine is experiencing an unprecedented focus on quantifying and improving health care quality. The American College of Cardiology (ACC) and the American Heart Association (AHA) have developed a multi-faceted strategy to facilitate the process of improving clinical care. The initial phase of this effort was to create clinical practice guidelines that carefully review and synthesize available evidence to better guide patient care. Such guidelines are written in a spirit of suggesting diagnostic or therapeutic interventions for patients in most circumstances. Accordingly, significant judgment by clinicians is required to adapt these guidelines to the care of individual patients, and these guidelines can be generated with varying degrees of confidence based upon available evidence. Occasionally, the evidence supporting a particular structural aspect or process of care is so strong that failure to perform such actions reduces the likelihood that optimal patient outcomes will occur. Creating a mechanism for quantifying these opportunities to improve the outcomes of care is an important and pressing challenge.
In the next phase of its quality improvement efforts, the ACC and the AHA created the ACC/AHA Task Force on Performance Measures in February 2000 to spearhead the development of performance measures that allow the quality of cardiovascular care to be assessed and improved. Three nominees from each organization were charged with the task of assembling teams of clinical and methodological experts, both from within the sponsoring organizations and from other organizations dedicated to the care of patients covered by the performance measurement set. These writing committees were given careful guidance with respect to the necessary attributes of good performance measures and the process of identifying, constructing, and refining these measures so that they can accurately achieve their desired goals (1) .
The role of performance measurement writing committees is not to perform a primary evaluation of the medical literature; this is undertaken by ACC/AHA guidelines committees. However, performance measurement writing committees work collaboratively with guidelines committees so that the guideline recommendations are written with a degree of specificity that supports performance measurement and so that new knowledge can be rapidly incorporated into performance measurement. Development of ACC/AHA guidelines includes a detailed review of and ranking of the evidence available for the diagnosis and treatment of specific disease areas. Published guideline recommendations employ the ACC/AHA classification system I, IIa, IIb, and III ( Fig. 1) .
So as not to duplicate performance measure development efforts, writing committees were also instructed to evaluate existing nationally recognized performance measures using the ACC/AHA "attributes of good performance measures. " The measure specifications were adopted for those performance measures that meet these criteria. Such measures have established validity, reliability, and feasibility and will form the foundation of the ACC/AHA measurement sets. Furthermore, writing committees are encouraged to identify additional performance measures that correspond to those key areas of quality proven to improve patient outcomes.
ACC/AHA Performance Measurement Sets are to be applied in either the inpatient and/or outpatient setting depending upon the topic. Although inpatient measures have traditionally been captured by retrospective data collection, the increased use of electronic medical records allows for prospective collection in the inpatient and outpatient settings. Prospective data collection is itself a continuous quality improvement process. The performance measures quantify explicit actions performed in carefully specified patients for whom adherence should be advocated in all but the most unusual circumstances. In addition, the measures are constructed with the intent to facilitate both retrospective and prospective data collection using explicit administrative and/or easily documented clinical criteria. Furthermore, the data elements required to construct the performance measures are identified and linked to existing ACC/AHA Clinical Data Standards to encourage the standardization of cardiovascular measurement.
While the focus of the performance measures writing committees is to develop measures for internal quality improvement, it is appreciated that other organizations may use these measures for external reporting of provider performance. Therefore, it is within the scope of the writing committee's task to comment on the strengths and limitations of externally reporting potential performance measures. Specifically, this was done in the inpatient measurement set, where a "Challenges to Implementation" section was included below the specification, when appropriate (see Appendix A).
All the measures contained in this set have limitations and challenges to implementation that could result in unintended consequences when used for accountability purposes. The implementation of these measures for purposes other than quality improvement (QI) require field testing to address issues related to, but not limited to, sample size, reasonable frequency of use for an intervention, comparability, and audit requirements. The way in which these issues are addressed will be highly dependent on the type of accountability system developed including data collection method, assignment of patients to physicians for measurement purposes, baseline measure setting, incentive system, and public reporting method among others. The ACC/AHA encourages those interested in working on implementation of these measures for purposes beyond QI to work with the ACC/AHA to understand these complex issues in pilot testing projects that can measure the impact of any limitations and provide guidance on possible refinements of the measures that would make them more suitable for additional purposes.
In the process of facilitating the measurement of cardiovascular health care quality, the ACC/AHA Performance Measurement Sets can serve as a vehicle for more rapidly translating the strongest clinical evidence into practice. These documents are intended to provide practitioners with "tools" for measuring the quality of care and for identifying opportunities to improve. Because the target audience and unit of analysis for these measures is the practitioner, they were constructed from the provider's perspective and were not intended to characterize "good" or "bad" practice but to be part of a system with which to assess and improve health care quality. It is our hope that an application of these performance measures within a system of QI will provide a mechanism through which the quality of medical care can be measured and improved.
Robert O. Bonow, MD, FACC, FAHA Chair, ACC/AHA Task Force on Performance Measures * Data available from clinical trials or registries about the usefulness/efficacy in different sub-populations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. † In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All recommendations in this guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers' comprehension of the guidelines and will allow queries at the individual recommendation level.
I. INTRODUCTION
The ACC/AHA ST-Elevation and Non-ST-Elevation Myocardial Infarction (STEMI/NSTEMI) Performance Measures Writing Committee was charged with the development of performance measures concerning the diagnosis and treatment of both ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) (see the Methodology section for detailed information on how the measures were constructed and selected.)
A. Scope of the Problem
Both STEMI and NSTEMI afflict an enormous number of people each year. The estimated incidence of myocardial infarction (MI) is 865 000 attacks annually. Twenty percent of men and 30% of women will die within 1 year after having an initial recognized MI. The risk of further cardiac disease complications, such as another heart attack, sudden death, angina pectoris, heart failure and stroke for those who survive an MI is substantial (2) .
Over the past 30 years, advances in cardiovascular care have resulted in a dramatic decline in mortality and morbidity associated with STEMI and NSTEMI (3). However, there is strong evidence that the best treatments and strategies for these patients are not always pursued. As a result, the outcomes of STEMI and NSTEMI patients are not as good as they could be with better translation of the best scientific knowledge to the bedside.
B. Writing Committee Structure/Members
The members of the ACC/AHA STEMI/NSTEMI Performance Measures Writing Committee included senior clinicians, a content expert on STEMI and NSTEMI performance measurement, a methodologist, and a statistician. The Writing Committee also included members of the American College of Physicians (ACP), American Academy of Family Physicians (AAFP), and the American College of Emergency Physicians (ACEP).
C. Independence/Relationships With Industry Disclosure
The work of the Writing Committee was supported exclusively by the ACC and the AHA. Writing Committee members volunteered their time, and there was no commercial support. Meetings of the Writing Committee were confidential and attended only by committee members and staff. All Writing Committee members with relationships with industry relevant to this topic declared these in writing according to standard ACC and AHA reporting requirements; additionally, members verbally acknowledged these relationships to the Writing Committee. Please see Appendix C for relevant Writing Committee relationships with industry. In addition, Appendix D includes relevant relationships with industry information for all peer reviewers of this document.
D. Review/Endorsement
During the period August 13, 2004 to September 13, 2004 , the ACC/AHA STEMI/NSTEMI Performance Measures document underwent a 30-day public comment period during which time ACC and AHA members, as well as other health professionals, had an opportunity to review and comment on the final draft document in advance of its final approval and publication. Over 40 responses were received.
The official peer and content review of the document was conducted simultaneously with the 30-day public comment period, with two peer reviewers nominated by the ACC and two reviewers nominated by the AHA. Additional comments were sought from clinical content experts and performance measurement experts.
The ACC/AHA Clinical Performance Measures for Adults with ST-Elevation and Non-ST-Elevation Myocardial Infarction was adopted by the respective Boards of the ACC and AHA on October, 2005. These measures will be reviewed for currency annually and will be updated as needed. They will be considered valid until they are updated or rescinded by the ACC/AHA Task Force on Performance Measures.
II. METHODOLOGY
The development of performance systems involves identification of a set of measures targeted toward a particular patient population, observed over a particular time period. To achieve this goal, the ACC/AHA Task Force on Performance Measures has outlined and published a methodology of sequential tasks that writing committees are required to complete (1). The following sections outline how these steps were applied by this Writing Committee.
A. Definition of STEMI/NSTEMI
The Writing Committee has incorporated the use of the terms STEMI and NSTEMI throughout this document along with the all-inclusive term acute myocardial infarction Committee has used the term AMI when the measure refers to both STEMI and NSTEMI patients, while the term STEMI was used in cases in which the clinical recommendation is specific to STEMI patients only. Measures specific to NSTEMI patients only are not contained in this set but may be considered in future updates.
Specific diagnosis codes, based on ICD-9-CM (Table 1) , should be used to screen and select the inpatient target patient population. These codes correspond to the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and Centers for Medicare and Medicaid services (CMS) AMI cohort selection codes.
B. Dimensions of Care
Given the multiple domains of providing care that can be measured, the Writing Committee identified and explicitly articulated the relevant dimensions of care that should be evaluated. As part of the methodology, each potential performance measure was categorized into its relevant dimension of care. Classification into dimensions of care facilitated identification of areas where evidence was lacking as well as prevented duplication of measures within the set. Diagnostics, patient education (including prognosis and etiology), and treatment were selected as the relevant dimensions of care for the STEMI/NSTEMI performance measures. Self-management and monitoring of disease status will be evaluated in the future for the inpatient setting. The committee exclusively focused on processes and did not consider outcomes, because the purpose of the measures are to assist physicians in improving specific clinical care.
C. Literature Review
As the primary sources for deriving these measures, this (6) . The Chair of this Writing Committee also participated on the Writing Committee of the latter guideline. As a participant on the guideline committee, the Chair was able to offer insights into measurement issues and provide suggestions for clarity and specificity of guideline recommendations. At the same time, the guideline contributed to the refinement of the measures developed by this Writing Committee.
In addition, existing measure sets, such as those developed by the JCAHO and CMS, were reviewed by the Writing Committee. See the Discussion section for details on our efforts to align our measures with CMS and JCAHO.
D. Definition and Selection of Measures
Explicit criteria exist for the development of performance measures so that they can accurately reflect the quality of care, including quantification of the numerator and denominators of potential measures and evaluating the interpretability, applicability, and feasibility of the proposed measure. To determine which measures would be considered for inclusion in the performance measurement set, the Writing Committee reviewed and prioritized the class I and class III recommendations as potential quality indicators from the AMI guideline, the UA/NSTEMI guideline, and the STEMI guideline (4 -6) .
From the analysis of these recommendations, the Writing Committee identified potential measures relevant to the treatment of STEMI and NSTEMI patients. Using the ACC/AHA performance measure rating form and guide (Appendix B), each Writing Committee member rated potential measures on 13 dimensions using a 5-point Likert scale (1 ϭ lowest rating; 5 ϭ highest rating) against the ACC/AHA attributes for good performance measures (Table 2).
The rating results of the final question on the rating form, "Overall Assessment," were used to make the final determination for inclusion of a potential measure in the measurement set. Any measure that received a full committee consensus rating of 3 or above in this area ("Overall Assessment") was advanced for full consideration by the Writing Committee.
In the case of the measure for angiotensin-converting enzyme inhibitor (ACEI), a Class IIa ACC/AHA STEMI guidelines recommendation for angiotensin receptor blockers (ARB) was considered and used as the basis for clarifying the measure constructed by the committee. Although class IIa recommendations are not considered for stand-alone measures, in some cases (such as this one) they provide additional information about valid alternative therapies that are considered by the committee for inclusion in a measure set.
III. STEMI/NSTEMI PERFORMANCE MEASURES

A. Inpatient Population and Care Period
The inpatient target population consists of patients aged 18 years or older with a principal discharge diagnosis of AMI (STEMI and NSTEMI) based on ICD-9-CM (Table 1) . A set of inclusion and exclusion criteria specific to each inpatient measure was developed. The general period of assessment is the related inpatient hospitalization. The specific time period of interest for each measure is further defined in the full measure specifications (Appendix A). Table 3 shows the ACC/AHA STEMI/NSTEMI performance measurement set-those with the highest level of evidence and full-consensus support among the committee members. The measures include aspirin therapy at arrival and discharge, beta-blocker therapy at arrival and discharge, low-density lipoprotein cholesterol (LDL-c) assessment, lipid-lowering therapy at discharge, ACEI, and/or ARB therapy, time-to-fibrinolytic therapy, time-to-percutaneous coronary intervention (PCI), reperfusion therapy, and smoking cessation advice/counseling.
B. Brief Summary of the Measurement Set
Appendix A provides the detailed specifications for each inpatient performance measure, including numerator, denominator, period of assessment, method of reporting, sources of data, rationale, corresponding guidelines, secondary measures to consider, and challenges to implementation. Acute myocardial infarction (AMI-STEMI and NSTEMI) patients without beta-blocker contraindications who received a beta-blocker within 24 hours after hospital arrival.
Beta-Blockers Prescribed at Discharge
Acute myocardial infarction (AMI-STEMI and NSTEMI) patients without beta-blocker contraindications who are prescribed a beta-blocker at hospital discharge.
LDL-Cholesterol Assessment
Acute myocardial infarction (AMI-STEMI and NSTEMI) patients with documentation of lowdensity lipoprotein cholesterol (LDL-c) level in the hospital record or documentation that LDL-c testing was done during the hospital stay or is planned for after discharge. 6. Lipid-Lowering Therapy at Discharge Acute myocardial infarction (AMI-STEMI and NSTEMI) patients with elevated low-density lipoprotein cholesterol (LDL-c Ն100 mg/dl or narrative equivalent) who are prescribed a lipidlowering medication at hospital discharge. 
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C. Data Collection
To aid in the collection of hospital data, use of a data collection tool or flow sheet is recommended. 
IV. DISCUSSION
The ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-ST-Elevation MI addresses many of the same processes of care as earlier measurement sets published by other organizations. These measures were developed by employing the ACC/AHA methodology for developing performance measure sets (3). The Writing Committee has been cognizant of the previous efforts of other groups and sought to enhance and clarify measures in ways that reflect the advancement of the underlying science, the complexity of care, and the challenges of accurate and complete data collection. As such, the Writing Committee has made every attempt to align these measures with those promulgated by CMS and JCAHO. This Writing Committee felt it was important to add exclusion criteria to the measures to recognize that there are justifiable medical and patient reasons for not meeting the performance measures. These reasons should be included in the "reasons documented by physician, nurse practitioner, or other health care provider for not. . ." Documentation of such factors should be encouraged and will provide valuable data for future research and conducting in-depth QI for situations where there seem to be outliers with respect to the number of patients with medical or patient-centered exclusions for the performance measures.
Challenges to implementation of measures are discussed, where applicable. In general, inadequate documentation is the initial challenge of any measurement effort. The fact that these challenges are discussed is not intended as an argument against measurement. Rather, they should be considered as cautionary notes that draw attention to areas where additional focus on research and improvement of the measures should be considered.
Four areas in this measurement set warrant further discussion: the addition of ARBs to the ACEI for left ventricular systolic dysfunction (LVSD) measure (#7), the use of "median" versus "mean" in the time-tofibrinolytic measure (#8), the new standard for the time-to-PCI measure (#9), and the new reperfusion therapy (#10) measure.
A. Addition of ARBs to ACEI Measure
The measurement set includes ARBs along with ACEI prescription on discharge. Although Class IIa recommendations are not considered for stand-alone measures, in this case, the additional information provided about valid alternative therapies allowed it to be considered for inclusion in the measure. This change is made with 
C. New Standard for Time-to-Primary PCI Measure
This measurement set establishes the time-to-PCI standard at 90 min, which is different than the 120-min standard used in the current CMS and JCAHO measures. This change reflects the new recommendation from the 2004 ACC/AHA STEMI guidelines that, "delay from patient contact with the health care system (typically, arrival at the emergency department or contact with paramedics) to balloon inflation should be less than 90 min" (6).
D. New Reperfusion Therapy Measure
The new reperfusion therapy measure is meant to capture the percentage of patients eligible for reperfusion (either fibrinolytic therapy or PCI) who are reperfused. This measure is meant to assist facilities in assessing the appropriateness of their use of reperfusion therapy and detecting underutilization of reperfusion. Although the Writing Committee considered a number of additional potential measures that focus on equally important aspects of care, either the evidence base or more significant challenges to measurement of these components of care across all patients undermined the benefits that might be gained. Of note, the committee discussed at length the possibility of including a clopidogrel measure and a measure for ACEI in patients with left ventricular ejection fraction (LVEF) greater than 0.40, but it felt that the evidence-base did not yet support their inclusion as a performance measure. The Writing Committee will monitor changes in the evidence in new clinical trials and will determine whether additional measures should be added in the future.
The ACC/AHA STEMI/NSTEMI performance measurement set should contribute to the evolution of reporting systems that allow physicians to improve care for a critical patient population. QI is a continuous process, and this document reflects the lessons the practicing community has learned to date in using existing measures and knowledge gained about how they might be improved. The clinical care team should collect data and review adherence to these measures on a routine basis, look for changes, and adjust practice patterns as necessary to improve performance. 
Sources of data
Administrative data and medical records.
Rationale
The use of aspirin has been shown to reduce mortality with AMI.
Corresponding Guideline(s)
ACC/AHA STEMI Guidelines (6) Class I Aspirin should be chewed by patients who have not taken aspirin before presentation with STEMI. The initial dose should be 162 mg (Level of Evidence: A) to 325 mg (Level of Evidence: C). Although some trials have used enteric-coated aspirin for initial dosing, more rapid buccal absorption occurs with non-enteric-coated aspirin formulations.
ACC/AHA UA/NSTEMI Guidelines (5)
Class I Antiplatelet therapy should be initiated promptly. Aspirin should be administered as soon as possible after presentation and continued indefinitely (Level of Evidence: A).
Method of Reporting
Aggregate rate (standard error) generated from count data reported as a proportion.
*This also includes aspirin intolerance.
Aspirin Prescribed at Discharge
Acute myocardial infarction (AMI-STEMI and NSTEMI) patients without aspirin contraindications who are prescribed aspirin at hospital discharge Numerator AMI patients who are prescribed aspirin at hospital discharge.
Denominator AMI patients without aspirin contraindications. Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 . -Aspirin allergy -Active bleeding on arrival or during hospital stay -Coumadin/warfarin prescribed at discharge -Other reasons documented by physician, nurse practitioner, or physician assistant for not prescribing aspirin at discharge*
Period of assessment
Hospital discharge.
Sources of data
Rationale
The use of aspirin has been shown to reduce recurrent MI and death in patients surviving an initial MI.
Corresponding Guideline(s)
ACC/AHA STEMI Guidelines (6) Class I A daily dose of aspirin (initial dose of 162 to 325 mg orally; maintenance dose of 75 to 162 mg) should be given indefinitely after STEMI to all patients without a true aspirin allergy (Level of Evidence: A).
ACC/AHA UA/NSTEMI Guidelines (5)
Method of Reporting
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Beta-Blocker at Arrival
Acute myocardial infarction (AMI-STEMI and NSTEMI) patients without beta-blocker contraindications who received a beta-blocker within 24 hours after hospital arrival Numerator AMI patients who received a beta-blocker within 24 hours after hospital arrival.
Denominator AMI patients without beta blocker contraindications. Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 .
Excluded populations:
• Patients less than 18 years of age • Patients transferred to another acute care hospital or federal hospital on day of or day after arrival • Patients received in transfer from another acute care hospital, including another emergency department.
• Patients discharged on day of arrival • Patients who expired on day of or day after arrival • Patients who left against medical advice on day of or day after arrival • Patients with one or more of the following beta-blocker contraindications/reasons for not prescribing beta-blocker documented in the medical record: -Beta-blocker allergy -Bradycardia (heart rate less than 60 beats/min) on arrival or within 24 hours after arrival while not on a beta-blocker -Heart failure on arrival or within 24 hours after arrival -Second-or third-degree heart block on ECG on arrival or within 24 hours after arrival and does not have a pacemaker -Shock on arrival or within 24 hours after arrival -Other reasons documented by a physician, nurse practitioner, or physician assistant for not giving a beta-blocker within 24 hours after hospital arrival*
Period of assessment
Within 24 hours after hospital arrival.
Sources of data
Rationale
To reduce ventricular arrhythmias, recurrent ischemia, reinfarction, and if given early enough, infarct size and short-term mortality.
Corresponding Guideline(s)
ACC/AHA STEMI Guidelines (6)
Class I
Oral beta-blocker therapy should be administered promptly to those patients without a contraindication, irrespective of concomitant fibrinolytic therapy or performance of primary PCI (Level of Evidence: A).
ACC/AHA UA/NSTEMI Guidelines (5)
Class I A beta-blocker, with the first dose administered intravenously if there is ongoing chest pain, followed by oral administration, in the absence of contraindications (Level of Evidence: B).
Method of Reporting
*This also includes beta-blocker intolerance.
Beta-Blocker Prescribed at Discharge
Acute myocardial infarction (AMI-STEMI and NSTEMI) patients without beta-blocker contraindications who are prescribed a beta-blocker at hospital discharge Numerator AMI patients who are prescribed a beta-blocker at hospital discharge.
Denominator AMI patients without beta-blocker contraindications. Included populations: Discharges with an ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 -Beta-blocker allergy -Bradycardia (heart rate less than 60 beats/min) on day of discharge or day prior to discharge while not on a betablocker -Second-or third-degree heart block on ECG on arrival or during hospital stay and does not have a pacemaker -Other reasons documented by a physician, nurse practitioner, or physician assistant for not prescribing a beta-blocker at discharge*
Period of assessment
Source of data
Rationale
Reduction in recurring events and long-term mortality.
Corresponding Guideline(s)
ACC/AHA STEMI Guidelines (6) Class I All patients after STEMI except those at low risk (normal or near-normal ventricular function, successful reperfusion, absence of significant ventricular arrhythmias) and those with contraindications should receive beta-blocker therapy. Treatment should begin within a few days of the event, if not initiated acutely, and continue indefinitely (Level of Evidence: A).
Class IIa
It is reasonable to prescribe beta-blockers to low-risk patients after STEMI who have no contraindications to that class of medications (Level of Evidence: A).
ACC/AHA UA/NSTEMI Guidelines (5) Class I Beta-blockers in the absence of contraindications (Level of Evidence: A).
Method of Reporting
*This also includes beta-blocker intolerance. 
Source of data
Rationale
Measurement of lipid levels in patients with STEMI and NSTEMI is essential to gauging the need for lipid-lowering therapy and/or dietary modification and assessing the risk of subsequent coronary events.
Lipid-Lowering Therapy at Discharge
Acute myocardial infarction (AMI-STEMI and NSTEMI) patients with elevated low-density lipoprotein-cholesterol (LDL-c >100 mg/dl or narrative equivalent) who are prescribed a lipid-lowering medication at hospital discharge.
Numerator AMI patients who are prescribed lipid-lowering medication at hospital discharge.
Denominator AMI patients with elevated LDL-c.
Included populations: Discharges with:
• An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 
Sources of data
Rationale
Multiple clinical trials have shown the benefit of lipid-lowering therapy for patients who have had an acute coronary event. Initiation of lipid-lowering therapy at discharge is preferred to enhance patient compliance with medication therapy. 
ACEI or ARB for LVSD at Discharge
Sources of data
Rationale
ACEIs have been shown to reduce mortality rates for patients with AMI (or who recently had an MI) and have LVSD (9 -13). Benefit has been greatest for those with anterior MI and those with greater LV dysfunction (LVEF Ͻ0.40). Benefit also has been shown in diabetic patients with LV dysfunction (14) . Current guidelines (5,6) recommend (Class I designation) in-hospital initiation (within 24 hours) and outpatient continuation indefinitely. The use of ARBs post-STEMI has not been as thoroughly explored as ACEIs in STEMI patients. The OPTIMAAL trial found no significant differences between losartan (target dose 50 mg once daily) and captopril (target dose 50 mg three times daily) in all-cause mortality (15); there was a trend toward better outcome with captopril. The VALIANT trial compared the effects of captopril (target dose 50 mg three times daily), valsartan (target dose 160 mg twice daily), and the combination (captopril target dose 50 mg three times daily; valsartan target dose 80 mg twice daily) on mortality in post-MI patients with LV dysfunction (16) . During a median follow-up of 24.7 months, death occurred in 19.9% of the valsartan group, 19.5% of the captopril group, and 19.3% of the combined group. Accordingly, guidelines suggest that valsartan monotherapy (target dose 160 mg twice daily) should be administered to STEMI patients who are intolerant of ACEIs and have evidence of LV dysfunction. However, guidelines also state that valsartan monotherapy can be a useful alternative to ACEIs-the decision in individual patients may be influenced by physician and patient preference, cost, and anticipated side-effect profile (6).
Time to Fibrinolytic Therapy
Median time from arrival to administration of fibrinolytic agent in patients with ST-segment elevation or left bundle branch block (LBBB) on the electrocardiogram (ECG) performed closest to hospital arrival time. Acute myocardial infarction (AMI-STEMI and LBBB only) patients receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 min or less.
Numerator AMI patients whose time from hospital arrival to fibrinolytic therapy is 30 min or less.
Denominator AMI patients with ST-elevation or LBBB on ECG who received fibrinolytic therapy. Included populations: Discharges with:
• An ICD-9-CM Principal Diagnosis Code for AMI as defined in Table 2 Period of assessment Within 6 hours after hospital arrival.
Sources of data
Rationale
There are a multitude of experimental and clinical studies that demonstrate that amount of myocardial salvage is directly related to time of fibrinolytic therapy administration. The earlier the treatment, the more myocardium is salvaged (i.e., "time is muscle"). Total time to fibrinolytic drug administration is dependent on a multitude of processes that begins on patient's arrival to the emergency department. The National Heart Attack Alert Program has chosen to focus on four D's of the overall process: Door, Data, Decision, and Delivery. The three easiest data points to measure on retrospective chart review are Door (arrival time), Data (ECG time), and Delivery (time of drug administration). Decision time can only be determined if the physician documents in the medical records the actual time that he/she gave the order for fibrinolytic drug administration. Data time only truly reflects actual data time if physician immediately reviews ECG results ("data not seen is data not done").
Corresponding Guideline(s)
Door-to-Data (ECG) Time ACC/AHA STEMI Guidelines (6)
Class I
A 12-lead ECG should be performed and shown to an experienced emergency physician within 10 min of emergency department arrival for all patients with chest discomfort (or anginal equivalent) or other symptoms suggestive of STEMI (Level of Evidence: C).
ACC/AHA UA/NSTEMI Guidelines (5)
A 12-lead ECG should be obtained immediately (within 10 min) in patients with ongoing chest discomfort and as rapidly as possible in patients who have a history of chest discomfort consistent with acute coronary syndrome but whose discomfort has resolved by the time of evaluation (Level of Evidence: C). 
Data-to-Decision Time
Class I
The delay from patient contact with the health care system (arrival at the emergency department or contact with paramedics) to initiation of fibrinolytic therapy should be less than 30 min. Alternatively, if PCI is chosen, the delay from patient contact with the health care system (typically, arrival at the emergency department or contact with paramedics) to balloon inflation should be less than 90 min (Level of Evidence: B). ACC/AHA Indications for Fibrinolytic Therapy-ST-Segment Elevation Cohort ACC/AHA STEMI Guidelines (6) Class I All STEMI patients should undergo rapid evaluation for reperfusion therapy and have a reperfusion strategy implemented promptly after contact with the medical system (Level of Evidence: A).
